Weekly Versus Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

John K. Chan; Mark F. Brady; Richard T. Penson; Helen Huang; Michael J. Birrer; Joan L. Walker; Paul A. Disilvestro; Stephen C. Rubin; Lainie P. Martin; Susan A. Davidson; Warner K. Huh; David M. O'Malley; Matthew P. Boente; Helen Michael; Bradley J. Monk

Article

Weekly Versus Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

Obstetrical and Gynecological Survey

DOI: 10.1097/OGX.0000000000000328

1Citations

21Readers

Get full text

Cite

CITATION STYLE

APA

Chan, J. K., Brady, M. F., Penson, R. T., Huang, H., Birrer, M. J., Walker, J. L., … Monk, B. J. (2016, June 1). Weekly Versus Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. Obstetrical and Gynecological Survey. Lippincott Williams and Wilkins. https://doi.org/10.1097/OGX.0000000000000328

Weekly Versus Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

Cite

Register to see more suggestions